| Distinct and convergent consequences of splice factor mutations in myelodysplastic syndromes |
|
American Journal of Hematology |
Myelodysplastic Syndromes (MDS) |
| The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion |
|
Annals of Hematology |
Myelodysplastic Syndromes (MDS) |
| Paroxysmal nocturnal hemoglobinuria without GPI-anchor deficiency |
|
The Journal of Clinical Investigation |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Similar outcomes of alemtuzumab-based hematopoietic cell transplantation for SAA patients older or younger than 50 years |
|
Blood Advances |
Aplastic Anemia |
| Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia |
|
Blood Advances |
Aplastic Anemia |
| DNA methylation identifies genetically and prognostically distinct subtypes of myelodysplastic syndromes |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| The evolving role of next generation sequencing in myelodysplastic syndromes |
|
British Journal of Haematology |
Myelodysplastic Syndromes (MDS) |
| Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence |
|
JCO Precision Oncology |
Myelodysplastic Syndromes (MDS) |
| Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria |
|
Therapeutic Advances in Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
